Rhythm Pharmaceuticals diskutieren
Rhythm Pharmaceuticals
WKN: A2H5A0 / Symbol: RYTM / Name: Rhythm Pharmaceuticals / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
45,60 €
-2,17 %
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $32.00 price target on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its "buy" rating re-affirmed by analysts at LADENBURG THALM/SH SH. They now have a $35.00 price target on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $40.00 to $45.00. They now have a "buy" rating on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target raised by analysts at Canaccord Genuity Group Inc. from $52.00 to $56.00. They now have a "buy" rating on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) was upgraded by analysts at Bank of America Co. from a "neutral" rating to a "buy" rating.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $32.00 price target on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target raised by analysts at Wells Fargo & Company from $38.00 to $40.00. They now have an "overweight" rating on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target raised by analysts at Needham & Company LLC from $32.00 to $45.00. They now have a "buy" rating on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $38.00 to $42.00. They now have a "buy" rating on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) was upgraded by analysts at Morgan Stanley from an "equal weight" rating to an "overweight" rating. They now have a $55.00 price target on the stock, up previously from $29.00.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target raised by analysts at Wells Fargo & Company from $48.00 to $53.00. They now have an "overweight" rating on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target raised by analysts at Needham & Company LLC from $45.00 to $50.00. They now have a "buy" rating on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $42.00 to $52.00. They now have a "buy" rating on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $50.00 price target on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $50.00 price target on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $50.00 price target on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $50.00 price target on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target lowered by analysts at Needham & Company LLC from $50.00 to $46.00. They now have a "buy" rating on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target raised by analysts at Needham & Company LLC from $46.00 to $55.00. They now have a "buy" rating on the stock.
Ratings data for RYTM provided by MarketBeat
Neueste Beiträge
Truist_Financial_Co_ in Pacira Pharmaceuticals diskutieren